ERBB2 and gastric cancer: Beyond molecular classification, some other molecular biomarkers, such as human epidermal growth factor-2 (HER-2), fibroblast growth factor receptor (FGFR), Claudin 18.2, and programmed death ligand 1 (PD-L1), have revolutionized the gastric cancer landscape, with proven prognostic and targetable value.